Genotype, phenotype, and medication recommendation agreement among commercial pharmacogenetic-based decision support tools

Pharmacogenomics Journal

Volumn 18, Issue 5, 2018, Pages 613-622

  Bousman, Chad A ^a,b   Dunlop, Boadie W ^c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF CALGARY   (Canada)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CATECHOL METHYLTRANSFERASE; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; HLA A ANTIGEN; HYPNOTIC AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT; SEROTONIN TRANSPORTER;

ARTICLE; BDNF GENE; CLINICAL ARTICLE; CLINICAL DECISION SUPPORT SYSTEM; COMT GENE; CROSS-SECTIONAL STUDY; CYP1A2 GENE; CYP2B6 GENE; CYP2C19 GENE; CYP2C9 GENE; CYP2D6 GENE; CYP3A4 GENE; GENE; GENOTYPE; HLA A GENE; HTR2A GENE; HTR2C GENE; HUMAN; OPRM1 GENE; OUTPATIENT; OVERLAPPING GENE; PHARMACOGENETIC TESTING; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; SLC6A4 GENE; TREATMENT RESISTANT DEPRESSION; UGT2B15 GENE; GENETICS; MAJOR DEPRESSION; PHARMACOGENETICS; PROCEDURES;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; CROSS-SECTIONAL STUDIES; DEPRESSIVE DISORDER, MAJOR; GENOTYPE; HUMANS; PHARMACOGENETICS; PHENOTYPE;

EID: 85047306533     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/s41397-018-0027-3     Document Type: Article

References (33)

1. Undurraga J, Baldessarini RJ. Randomized, placebo-controlled trials of antidepressants for acute major depression: thirty-year meta-analytic review. Neuropsychopharmacology. 2012;37:851–64
2. Papakostas GI, Fava M, Thase ME. Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches. Biol Psychiatry. 2008;63:699–704
3. Zhou X, Ravindran AV, Qin B, Del Giovane C, Li Q, Bauer M, et al. Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis. J Clin Psychiatry. 2015;76:e487–98
4. Dunlop BW. Prediction of treatment outcomes in major depressive disorder. Expert Rev Clin Pharmacol. 2015;8:669–72
5. Fabbri C, Porcelli S, Serretti A. From pharmacogenetics to pharmacogenomics: the way toward the personalization of antidepressant treatment. Can J Psychiatry. 2014;59:62–75
6. Reynolds GP, McGowan OO, Dalton CF. Pharmacogenomics in psychiatry: the relevance of receptor and transporter polymorphisms. Br J Clin Pharmacol. 2014;77:654–72
7. Conrado DJ, Rogers HL, Zineh I, Pacanowski MA. Consistency of drug–drug and gene–drug interaction information in US FDA-approved drug labels. Pharmacogenomics. 2013;14:215–23
8. Tansey KE, Guipponi M, Hu X, Domenici E, Lewis G, Malafosse A, et al. Contribution of common genetic variants to antidepressant response. Biol Psychiatry. 2013;73:679–82
9. Hicks JK, Bishop JR, Sangkuhl K, Muller DJ, Ji Y, Leckband SG, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther. 2015;98:127–34
10. Hicks JK, Sangkuhl K, Swen JJ, Ellingrod VL, Muller DJ, Shimoda K, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102:37–44
11. Leckband SG, Kelsoe JR, Dunnenberger HM, George AL, Tran E, Berger R, et al. Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and carbamazepine dosing. Clin Pharmacol Ther. 2013;94:324–8
12. Padmanabhan S. Handbook of pharmacogenomics and stratified medicines. Cambridge, MA: Academic Press; 2014
13. Amstutz U, Shear NH, Rieder MJ, Hwang S, Fung V, Nakamura H, et al. Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions. Epilepsia. 2014;55:496–506
14. Bousman CA, Hopwood M. Commercial pharmacogenetic-based decision-support tools in psychiatry. Lancet Psychiatry. 2016;3:585–90
15. Singh AB. Improved antidepressant remission in major depression via a pharmacokinetic pathway polygene pharmacogenetic report. Clin Psychopharmacol Neurosci. 2015;13:150–6
16. Winner JG, Carhart JM, Altar CA, Allen JD, Dechairo BM. A prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder. Discov Med. 2013;16:219–27
17. Perez V, Salavert A, Espadaler J, Tuson M, Saiz-Ruiz J, Saez-Navarro C, et al. Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial. BMC Psychiatry. 2017;17:250
18. Brennan FX, Gardner KR, Lombard J, Perlis RH, Fava M, Harris HW, et al. A naturalistic study of the effectiveness of pharmacogenetic testing to guide treatment in psychiatric patients with mood and anxiety disorders. Prim Care Companion CNS Disord. 2015;17:73–9
19. Hall-Flavin DK, Winner JG, Allen JD, Carhart JM, Proctor B, Snyder KA, et al. Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting. Pharmacogenet Genom. 2013;23:535–48
20. Hall-Flavin DK, Winner JG, Allen JD, Jordan JJ, Nesheim RS, Snyder KA, et al. Using a pharmacogenomic algorithm to guide the treatment of depression. Transl Psychiatry. 2012;2:e172
21. Bousman CA, Muller DJ, Ng CH, Byron K, Berk M, Singh AB. Concordance between actual and pharmacogenetic predicted desvenlafaxine dose needed to achieve remission in major depressive disorder: a 10-week open-label study. Pharmacogenet Genom. 2017;27:1–6
22. Brown LC, Lorenz RA, Li J, Dechairo BM. Economic utility: combinatorial pharmacogenomics and medication cost savings for mental health care in a primary care setting. Clin Ther. 2017;39:592–602
23. Espadaler J, Tuson M, Lopez-Ibor JM, Lopez-Ibor F, Lopez-Ibor MI. Pharmacogenetic testing for the guidance of psychiatric treatment: a multicenter retrospective analysis. CNS Spectr. 2017;22:315–24
24. Fagerness J, Fonseca E, Hess GP, Scott R, Gardner KR, Koffler M, et al. Pharmacogenetic-guided psychiatric intervention associated with increased adherence and cost savings. Am J Manag Care. 2014;20:e146–56
25. Winner J, Allen JD, Altar CA, Spahic-Mihajlovic A. Psychiatric pharmacogenomics predicts health resource utilization of outpatients with anxiety and depression. Transl Psychiatry. 2013;3:e242
26. Winner JG, Dechairo B. Combinatorial versus individual gene pharmacogenomic testing in mental health: a perspective on context and implications on clinical utility. Yale J Biol Med. 2015;88:375–82
27. Winner JG, Carhart JM, Altar CA, Goldfarb S, Allen JD, Lavezzari G, et al. Combinatorial pharmacogenomic guidance for psychiatric medications reduces overall pharmacy costs in a 1 year prospective evaluation. Curr Med Res Opin. 2015;31:1633–43
28. Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas. 1960;20:37–46
29. Umesh UN, Peterson RA, Sauber MH. Interjudge agreement and the maximum value of kappa. Educ Psychol Meas. 1989;49:835–50
30. McHugh ML. Interrater reliability: the kappa statistic. Biochem Med. 2012;22:276–82
31. Kraft JB, Slager SL, McGrath PJ, Hamilton SP. Sequence analysis of the serotonin transporter and associations with antidepressant response. Biol Psychiatry. 2005;58:374–81
32. Huezo-Diaz P, Uher R, Smith R, Rietschel M, Henigsberg N, Marusic A, et al. Moderation of antidepressant response by the serotonin transporter gene. Br J Psychiatry. 2009;195:30–8
33. Poolsup N, Li Wan Po A, Knight TL. Pharmacogenetics and psychopharmacotherapy. J Clin Pharm Ther. 2000;25:197–220